Lactobacillus sake and application thereof
The bacterin KK-31 produced by Lactobacillus sake SNL047 solves the problem of ineffectiveness against Gram-negative bacteria, achieves antibacterial, antitumor and antiviral effects on a variety of microorganisms, and provides food preservation and drug applications. Innovative solutions.
Patent Information
- Application Number
- CN202411081357.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-22
AI Technical Summary
Existing lactic acid bacteria such as nisin can only kill gram-positive bacteria and are ineffective against gram-negative bacteria. With the development of antibiotic resistance, existing drugs are gradually ineffective, and new polypeptide antibacterial agents are urgently needed to deal with it. Pathogenic infection and bacteriophageal bacterial infection have not been found.
Provide a strain of Lactobacillus sakei SNL047 and its bacterial steril KK-31, which has antibacterial activity against a variety of spoilage and pathogenic microorganisms, including pectin, Bacillus subtilis, E. coli, etc., and It has anti-tumor and anti-viral effects.
Bactericin KK-31 significantly inhibits food spoilage, pathogenic infection, tumor cell growth and viral replication, and has low toxicity and provides natural drug resources for food anti-corrosion, anti-infection, anti-tumor and anti-viral.
Smart Images

Figure CN118995487A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, in particular to a Lactobacillus sakei strain and application thereof. Background Art
[0003] Microorganisms are one of the main reasons for the decay of agricultural products during storage, transportation, and sales. Controlling the growth of spoilage microorganisms is the most fundamental way to reduce the loss of agricultural products due to decay. With the growing demand for green, safe, and healthy food, biological preservation has become a trend in the development of preservatives. Lactic acid bacteria bacteriocins are a class of polypeptides with antibacterial activity produced by lactic acid bacteria. After entering the human body, they are hydrolyzed into amino acids by digestive enzymes. They have the advantages of safety, high efficiency, and no residue, and have become the focus of research and development of biological preservatives or antibacterial drugs.
[0004] Nisin has been used in more than 50 countries around the world. In my country's national standard for food additives, GB2760 National Food Safety Standard for the Use of Food Additives, nisin has been allowed to be used in a variety of foods such as milk, meat, rice and flour products, beverages, and condiments. Nisin is also the only widely used lactic acid bacteriocin. However, nisin can only kill Gram-positive bacteria and is ineffective against Gram-negative bacteria. However, Gram-negative bacteria account for a large proportion of microorganisms that cause food spoilage. Therefore, there is an urgent need to develop lactic acid bacteriocins that can kill Gram-negative bacteria.
[0005] In recent years, with the development of antibiotic resistance, existing drugs have gradually become ineffective or even ineffective. Therefore, it is urgent to develop new antibacterial drugs to deal with pathogenic bacteria infections. Peptide antibacterial agents have a unique mechanism of action that makes it difficult for bacteria to develop resistance to them, and are not prone to cross-resistance with other types of antibiotics, becoming the focus of new drug research and development.
[0006] Vancomycin and colistin are both peptide antibiotics. Vancomycin is considered the "last line of defense" for humans against Gram-positive bacterial infections. Colistin is considered the "last line of defense" for humans against Gram-negative bacterial infections. However, drug-resistant bacteria have emerged for both vancomycin and colistin. Therefore, new peptide antibacterial agents need to be developed.
[0007] In 2015, the top journal Nature reported a new antibacterial agent, teixobactin, which is a new peptide antibacterial agent. In 2023, the top journal Cell reported a new antibacterial agent, clovibactin, which is also a new peptide antibacterial agent. It can be seen that peptide antibacterial agents have become a battleground for the development of new anti-infective drugs. As a highly safe antimicrobial peptide, lactic acid bacteria bacteriocin is one of the best choices for the development of new anti-infective drugs.
[0008] Although bacteriocins were first noticed as antibacterial agents, in the past 20 years, more and more researchers have found that some bacteriocins also have anti-tumor or anti-viral activities. However, bacteriocins that have the triple functions of antibacterial, anti-tumor and anti-viral have not yet been reported or discovered.
[0009] Therefore, how to provide a strain of sake Lactobacillus, bacteriocin and application thereof has become a technical problem to be solved by those skilled in the art. Summary of the invention
[0010] In view of this, one of the objects of the present invention is to provide a strain of lactic acid bacteria and a bacteriocin produced thereby, which can control a variety of spoilage microorganisms and pathogenic microorganisms; a second object is to provide the application of the bacteriocin in products for controlling food spoilage losses and treating pathogenic bacteria infections; a third object is to provide the application of the bacteriocin as an active peptide product developed, which has antibacterial, antitumor and antiviral functions.
[0011] After research, the present invention provides the following technical solutions:
[0012] 1. Lactobacillus sakei SNL047, the deposit number is CGMCC No.27632.
[0013] The sake Lactobacillus SNL047 of the present invention was isolated from homemade bacon of a citizen's family in Nanchong City, Sichuan Province, and was deposited in the General Microbiology Center of China Culture Collection Administration (CGMCC for short, address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing) on June 14, 2023, with a deposit number of CGMCC No. 27632, and a classification name of Lactobacillus sakei.
[0014] 2. Bacteriocin KK-31 produced by Lactobacillus sakei SNL047, the amino acid sequence of the bacteriocin precursor is
[0015] 3. Application of bacteriocin KK-31 of Lactobacillus sakei SNL047 in food spoilage control.
[0016] Furthermore, Pectobacterium carotovorum and Bacillus subtilis are preferred. The MIC value of the bacteriocin to Pectobacterium carotovorum is 16 μM, and the MIC value to Bacillus subtilis is 8 μM.
[0017] 4. Application of Lactobacillus sakei SNL047 and its bacteriocin KK-31 in controlling pathogenic bacteria infection.
[0018] Furthermore, the pathogen is preferably one or more of Escherichia coli O157:H7, Salmonella, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, and Cronobacter sakazakii; wherein the MIC value of the bacteriocin to Escherichia coli O157:H7 is 8-16 μM, and the MIC value to colistin-resistant Escherichia coli is 16 μM; the MIC value to Salmonella typhimurium, Salmonella enteritidis, and multidrug-resistant Salmonella is 16 μM; the MIC value to Pseudomonas aeruginosa is 32 μM; the MIC value to Klebsiella pneumoniae is 32 μM; the MIC value to Acinetobacter baumannii is 16 μM; and the MIC value to Cronobacter sakazakii is 64 μM.
[0019] 5. Application of bacteriocin KK-31 in inhibiting tumor cell growth.
[0020] Furthermore, the tumor cells are preferably human lung cancer cells A549 ATCC CCL-185.
[0021] 6. Application of bacteriocin KK-31 in inhibiting viral growth.
[0022] Furthermore, the virus is preferably porcine pseudorabies virus.
[0023] 7. Application of Lactobacillus sakei SNL047 and its bacteriocin KK-31 in the preparation of food preservation products.
[0024] 8. Application of Lactobacillus sakei SNL047 and its bacteriocin KK-31 in the preparation of anti-infective drug products.
[0025] 9. Application of Lactobacillus sakei SNL047 and its bacteriocin KK-31 in the preparation of anti-tumor drug products.
[0026] 10. Application of Lactobacillus sakei SNL047 and its bacteriocin KK-31 in the preparation of antiviral drug products.
[0027] The beneficial effects of the present invention are:
[0028] The invention discloses Lactobacillus sakei with a deposit number of CGMCC No. 27632, whose bacterial body exhibits strong inhibitory ability to pectin bacteria, and the bacteriocin KK-31 produced by the bacteria exhibits strong antibacterial activity to various Gram-negative pathogens, can reduce vegetable rot losses caused by pectin bacteria, and significantly reduce the incidence rate and lesion diameter; can treat human skin pathogen infection caused by Escherichia coli O157: H7, kill pathogens, and reduce tissue lesions; and has tumor cell inhibition activity and antiviral activity; in addition, the bacteriocin KK-31 has low toxicity, and its toxicity to greater wax moth is comparable to that of the commercial bacteriocin nisin. The invention not only provides a good antagonistic strain and food biological preservative for food spoilage control, but also provides a good natural drug resource for human / animal pathogen infection, tumor, and virus infection control. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0030] Figure 1 This is a double-layer streak plate diagram of the antibacterial activity of Lactobacillus sakei SNL047 against food spoilage bacteria Pectobacterium in Example 1 of the present invention;
[0031] Figure 2 This is a diagram showing the bacteriocin gene cluster of Lactobacillus sakei SNL047 mined from the BAGEL4 database in Example 2 of the present invention;
[0032] Figure 3 This is a comparison diagram of the amino acid sequence BLAST of the bacteriocin KK-31 precursor in Example 2 of the present invention on NCBI;
[0033] Figure 4This is a diagram showing the effect of low concentration bacteriocin KK-31 on vegetable rot control in Example 3 of the present invention;
[0034] Figure 5 This is a diagram showing the effect of bacteriocin KK-31 in Example 3 of the present invention on inhibiting pathogenic bacteria infection in human skin tissue;
[0035] Figure 6 This is a bar graph showing the effect of bacteriocin KK-31 on the survival rate of human non-small cell lung cancer cells ATCC CCL-185 in Example 3 of the present invention;
[0036] Figure 7 The diagram is a graph showing the inhibitory effect of bacteriocin KK-31 on pseudorabies virus (PRV) in Example 3 of the present invention, including microscopic observation (A), virus titer (B) and intracellular PRV gE protein expression level (C);
[0037] Figure 8 This is a diagram showing the effect of bacteriocin KK-31 in Example 3 of the present invention on the inhibition of pseudorabies virus (PRV), in which immunofluorescence detection of gE protein expression is performed;
[0038] Fig. 9 This is a bar graph of the toxicity (CCK8 method) of bacteriocin KK-31 to PK-15 cells in Example 4 of the present invention;
[0039] Fig.10 This is a diagram showing the effect of bacteriocin KK-31 on the survival rate of greater wax moth in Example 4 of the present invention. DETAILED DESCRIPTION
[0040] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, and preferably the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.
[0041] In the description of the present invention, it should be understood that the terms "length", "width", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, in the description of the present invention, "multiple" means two or more, unless otherwise clearly and specifically defined.
[0042] Example 1: Antibacterial activity of Lactobacillus sakei SNL047:
[0043] 1. Isolation of microorganisms:
[0044] S1: Put bacon (obtained from a family in Nanchong City, Sichuan Province) into a mortar containing physiological saline and grind it;
[0045] S2: dilute with sterile saline in a 10-fold dilution gradient;
[0046] S3: 100 μL of each dilution of the grinding solution was spread on MRS solid medium containing 2% CaCO3 and cultured at 37°C for 48 h;
[0047] S4: Pick a single lactic acid bacteria colony containing a calcium-soluble circle, and further use the streak separation method to repeatedly separate and purify the characteristic colonies, and record the morphological characteristics of each colony.
[0048] Colony morphological characteristics of SNL047 strain: On MRS agar plates, the colonies are round, have neat edges, are milky white, and have a moist surface that is easy to pick up.
[0049] 2. Antibacterial activity of antibacterial lactic acid bacteria:
[0050] Screening of antibacterial lactic acid bacteria using the double streak method:
[0051] S1: Inoculate lactic acid bacteria into MRS liquid medium and culture until OD 600nm =0.8;
[0052] S2: Use an inoculation loop to streak the bacterial suspension onto an MRS agar plate (two parallel lines, about 2 cm in length) and incubate at 37°C for 24 h.
[0053] S3: 10mL containing 10 6 LB agar medium (0.7 wt% agar) containing CFU / mL of food spoilage bacteria was poured onto the surface of the MRS agar plate, cultured at a constant temperature of 37°C for 24 h, and the size of the inhibition zone was observed.
[0054] The results are as follows Figure 1 As shown, strain SNL047 exhibited a strong inhibition zone against food spoilage bacteria Pectobacterium truncatum and had good antibacterial activity.
[0055] 3. Identification of microbial strains:
[0056] S1: The SNL047 strain was inoculated into MRS liquid medium and cultured at 37°C for 12 h;
[0057] S2: 16S rDNA was amplified by colony PCR using 27F (5'-agagagtttgatcmtggctcag-3') and 1495R (5'-ggttaccttgttacgactt-3') as primers, and the PCR amplification products were sequenced and analyzed.
[0058] The obtained 16s rDNA sequence of the SNL047 strain is as follows:
[0059]
[0060]
[0061] A BLAST comparison analysis was performed in the NCBI database, and the results showed that the Identity of the SNL047 strain and Lactobacillus sakei was 99% (>97%). Therefore, the SNL047 strain is Lactobacillus sakei, which is named SNL047 and deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration (referred to as CGMCC, address: No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing) on June 14, 2023, with a deposit number of CGMCC No. 27632.
[0062] Example 2: Identification of bacteriocin from Lactobacillus sakei SNL047:
[0063] S1: inoculating Lactobacillus sakei SNL047 seed bacteria into MRS liquid culture medium at an inoculum amount of 1 wt%;
[0064] S2: The genome of lactic acid bacteria was extracted by shaking flask culture at 37°C until the logarithmic phase;
[0065] S3: sequencing was performed using a BGISEQ instrument (BGI Tech, China) according to the manufacturer’s instructions;
[0066] S4: Use SPAdes to assemble the genome sequence using the clean raw data obtained;
[0067] S5: The obtained fasta format genome sequence was used to predict the bacteriocin gene cluster using BAGEL4 (http: / / bagel4.molgenrug.nl / ).
[0068] The results are as follows Figure 2 As shown, a bacteriocin gene cluster was obtained, and its classification annotation was putative bacteriocin. The gene cluster contained a bacteriocin precursor, and its full-length sequence was And the BLAST amino acid sequence alignment was performed in the NCBI database.
[0069] The results are as follows Figure 3 As shown, a total of 6 records were matched, among which the similarity with the hypothetical proteins of 2 strains of Latilactobacillus sakei was greater than 95%, and the similarity with the hypothetical proteins or Bac2 of Pediococcus, Weissella confusa, Leuconostoc citreum was less than 50%.
[0070] It can be seen from this that the product encoded by the bacteriocin precursor is a hypothetical protein with unknown function. We named the mature bacteriocin KK-31.
[0071] Example 3: Functional analysis and application of bacteriocin KK-31:
[0072] 1. Antibacterial activity of bacteriocin KK-31:
[0073] S1: The antibacterial activity of bacteriocin KK-31 against different spoilage bacteria and pathogens was determined according to the broth dilution method specified in the 30th edition of the Clinical and Laboratory Standards Institute (CLSI);
[0074] S2: bacteriocin powder (purity > 95%) dissolved in sterile water to a concentration of 2560 μM as the stock solution;
[0075] S3: In a 96-well plate, dilute bacteriocin KK-31 to 64, 32, 16, 8, 4, 2, or 1 μM using MH broth or TSB broth, with a volume of 200 μL per well;
[0076] S4: Add spoilage bacteria or pathogenic bacteria suspension to the well to a concentration of 10 6 CFU / mL;
[0077] S5: Culture at 37℃ or 28℃ for 18-24h, observe the bacterial growth, and record the MIC value of bacteriocin KK-31 against different spoilage bacteria and pathogens.
[0078] The results are shown in Table 1. The MIC value of the bacteriocin against Bacillus pectinus was 16 μM, and the MIC value against Bacillus subtilis was 8 μM. Furthermore, the MIC value of the bacteriocin against Escherichia coli O157:H7 was 8-16 μM, and the MIC value against colistin-resistant Escherichia coli was 16 μM; the MIC value against Salmonella typhimurium, Salmonella enteritidis, and multidrug-resistant Salmonella was 16 μM; the MIC value against Pseudomonas aeruginosa was 32 μM; the MIC value against Klebsiella pneumoniae was 32 μM; the MIC value against Acinetobacter baumannii was 16 μM; and the MIC value against Cronobacter sakazakii was 64 μM.
[0079] Table 1 MIC values of bacteriocin KK-31 against different spoilage bacteria and pathogens
[0080]
[0081]
[0082] In Table 1, a is Escherichia coli containing the colistin resistance gene MCR-1; b is a multidrug-resistant bacterium, and the drugs it is resistant to include ampicillin, amoxicillin, amikacin, ciprofloxacin, cefoperazone, ceftriaxone sodium, gatifloxacin, gentamicin, kanamycin, levofloxacin, nalidixic acid, co-trimoxazole, and tetracycline.
[0083] 2. Application of bacteriocin KK-31 in controlling vegetable rot:
[0084] S1: Dissolve mature bacteriocin KK-31 in sterile water to a concentration of 1 μM for later use;
[0085] S2: Prepare fresh green peppers and fresh celery (use the celery stalks), disinfect them with 2% sodium hypochlorite for 5 minutes, and then rinse them with tap water;
[0086] S3: Use a sterile puncher to punch holes on the surface of the green pepper and celery sticks, and add 10 μL of the spoilage bacteria pectinobacterium suspension (10 4 CFU / mL);
[0087] S4: After the bacterial suspension is completely absorbed, 20 μL of 1 μM bacteriocin KK-31 solution is added to each well;
[0088] S5: After the samples are completely absorbed, pack them in fresh-keeping boxes and store them at 28°C and 85% RH to observe the decay of the vegetables.
[0089] The results are as follows Figure 4As shown, on the second day of storage, the celery stalks in the control group showed obvious soft rot and browning, and some celery stalks were almost completely rotten, while only a small part of the celery stalks in the 1_μM bacteriocin KK-31 treatment group showed rot symptoms, and the rotten area was smaller; on the fourth day of storage, the peppers in the control group rotted significantly, and the pepper cells showed obvious collapse after cell wall degradation, and yellow-brown juice flowed out, accompanied by a foul odor, while the rot symptoms of the peppers in the 1_μM bacteriocin KK-31 treatment group were significantly alleviated, and only some peppers showed water-soaked tissue.
[0090] It can be seen that even at low concentration (1 μM), bacteriocin KK-31 still exhibits a good preservative effect and reduces food spoilage losses.
[0091] 3. Application of bacteriocin KK-31 in controlling pathogenic bacteria infection:
[0092] S1: Dissolve bacteriocin KK-31 in sterile water to a concentration of 200 μM for later use;
[0093] S2: E. coli O157:H7 was first injected into human skin, followed by 200 μM of bacteriocin KK-31. Figure 5 As shown in A (human skin purchased from Genoskin Company in Europe);
[0094] S3: Then cultured at 37°C;
[0095] S4: Control 1 was not inoculated with E. coli and was not treated with bacteriocin (uninfected), and control 2 was inoculated with E. coli and treated with PBS instead of bacteriocin (PBS-treated);
[0096] S5: Take samples at 0, 1, 3, and 6 hours, and count the coatings.
[0097] The results are as follows Figure 5 As shown in B, no E. coli O157:H7 was detected in the skin tissue of the control group 1 (uninfected), and the skin tissue section results showed that the tissue was in good condition and had no damage; the number of E. coli O157:H7 in the skin tissue of the control group 2 (PBS-treated) gradually increased with the extension of the treatment time, from less than 10 at 0 h to 5 The CFU increased to more than 10 in 6 hours 8 CFU, skin tissue section results showed that cells were dispersed and bacteria were visible in the tissue (arrow); the number of Escherichia coli O157:H7 in the skin tissue of the bacteriocin KK-31-treated group (KK31-treated) gradually decreased with the extension of treatment time. At 6 hours, the number of viable bacteria had dropped below the detection limit. The tissue morphology of the skin tissue section results was close to that of the control 1, and there was no obvious tissue damage.
[0098] It can be seen that bacteriocin KK-31 has good application potential in inhibiting pathogen infection.
[0099] 4. Bacteriocin KK-31 inhibits cancer cell proliferation activity:
[0100] S1: Analysis of the anticancer activity of bacteriocins using human non-small cell lung cancer cells ATCC CCL-185;
[0101] S2: In a 96-well plate, bacteriocin KK-31 was added to the culture medium of freshly cultured cancer cells at concentrations of 128 μM, 64 μM, 32 μM, 16 μM, 8 μM, 4 μM, 2 μM, and 0 μM, respectively, and cultured at 37 °C for 24 h;
[0102] S3: 0.5 mg / mL MTT was then added, and the supernatant was removed after 4 h of treatment;
[0103] S4: Finally, DMSO was added to dissolve the formazan, and the absorbance was measured at 549 nm to calculate the survival rate of cancer cells.
[0104] The results are as follows Figure 6 As shown, within the concentration range of 2-32 μM, the survival rate of human non-small cell lung cancer cells after treatment with bacteriocin KK-31 decreased to about 60%, and the survival rate decreased to about 50% after treatment with 64 μM bacteriocin KK-31. When the concentration of bacteriocin KK-31 increased to 128 μM, the survival rate of cancer cells was further reduced to about 20%.
[0105] These results suggest that bacteriocin KK-31 has anticancer activity.
[0106] 5. Antiviral activity of bacteriocin KK-31:
[0107] Porcine pseudorabies virus (PRV) is an alpha herpes virus that can cause reproductive disorders in sows and neurological symptoms in piglets, causing huge economic losses to the pig industry. At present, vaccines cannot completely eliminate the infection of the virus in clinical practice, and new antiviral drugs or preparations are urgently needed as a supplement to vaccine prevention and control strategies. In this study, the porcine kidney epithelial cell line PK-15 was selected as a cell model of PRV infection, and the inhibitory effect and effect of KK-31 on viral infection and replication were evaluated.
[0108] (1) Virus titer determination:
[0109] S1: Use Vero cells to plate several 96-well plates. After the cells are fully grown, PK-15 cells are infected with PRV at an MOI of 0.1 and used as the infection control group;
[0110] S2: cells were infected simultaneously with 1 μM, 5 μM, and 25 μM KK-31 and PRV (MOI = 0.1) as the KK-31 treatment group;
[0111] S3: The cells were placed in a 37°C incubator containing 5% CO2 and cultured. After 24 hours of PRV infection, the cell supernatant was collected for virus titer determination;
[0112] S4: Calculation of virus TCID using the Reed-Muench method 50 .
[0113] (2) Western blot detection of viral capsid protein levels:
[0114] S1: PK-15 cells were infected with PRV at MOI = 0.1 and served as the infection control group;
[0115] S2: cells were infected with 1 μM, 5 μM, and 25 μM KK-31 and PRV (MOI = 0.1) at the same time as the KK-31 treatment group;
[0116] S3: Cells were collected 24 hours after PRV infection. After the cells were fully lysed, the cell lysate was collected for SDS-PAGE electrophoresis, membrane transfer, blocking, antibody incubation, and detection imaging.
[0117] The results are as follows Figure 7 As shown in A, the cells in the blank group were spindle-shaped and closely distributed between cells, while the PRV-infected group showed typical pathological characteristics, with cells in a crater-like shape. The cells in the 25μM bacteriocin KK-31-treated group were similar to the blank group, without any pathological changes. The results of virus titer determination showed that different concentrations of KK-31 had a significant inhibitory effect on PRV infection, among which 25μM KK-31 treatment could reduce the virus titer of PRV by more than 10 times ( Figure 7 B). Western-blot results showed that 5μM and 25μM KK-31 treatment led to a significant decrease in the expression of PRV-specific protein gE in cells, suggesting that KK-31 can significantly inhibit PRV protein expression and viral infection ( Figure 7 C).
[0118] (3) Immunofluorescence test:
[0119] S1: cells were inoculated in 48-well cell culture plates and cultured for 24 h, PK-15 cells were infected with PRV at MOI = 0.5, and KK-31 treatment groups were set up in which cells were infected simultaneously with 1 μM, 5 μM, and 25 μM KK-31 and PRV (MOI = 0.5);
[0120] S2: Place the loaded 48-well plate in a 37°C cell culture incubator and culture for 48 hours;
[0121] S3: Then, the cells were treated with 4% paraformaldehyde, 0.1% Triton X-100, 5% BSA, primary antibody (gE monoclonal antibody), and fluorescent secondary antibody. The cells were washed three times with sterile PBS between each treatment. DAPI was added and the cells were incubated at room temperature in the dark for 5 min.
[0122] S4: After washing, the results were observed under an inverted fluorescence microscope.
[0123] The results are as follows Figure 8 As shown in the figure, the specific fluorescence of PRV gE protein in the cells treated with 25 μM KK-31 was significantly weakened, further confirming that KK-31 has a significant inhibitory effect on PRV infection in PK-15 cells, and the inhibitory effect of 25 μM KK-31 is the most obvious. It can be seen that bacteriocin KK-31 has antiviral activity.
[0124] Example 4: Evaluation of the safety of bacteriocin KK-31:
[0125] 1. Cell experiment:
[0126] S1: Cell viability assay was performed according to the instructions of the CCK-8 kit (Biomed), PK-15 cell suspension was inoculated into a 96-well plate, and cultured in an incubator at 37°C and 5% CO2;
[0127] S2: When the cell monolayer confluence reaches 80%, the KK-31 treatment groups are divided into groups according to the final concentrations of 0 μM, 1 μM, 5 μM and 25 μM, and a blank group (wells with only DMEM medium) and a control group (wells with only DMEM medium and cells) are set up;
[0128] S3: After culturing in a 37°C 5% CO2 incubator for 24 h, the supernatant was discarded and replaced with 100 μL of fresh culture medium containing 10% CCK-8 reagent;
[0129] S4: Incubate at 37℃ for about 1 hour, and measure the absorbance at 450nm using an enzyme reader. Cell viability = [OD 450nm (Treatment group)-OD 450nm (blank) / OD 450nm (Control group)-OD 450nm (blank)].
[0130] The experimental results are as follows Fig. 9 As shown, there was no significant difference between the groups treated with three concentrations of bacteriocin KK-31 and the control group, indicating that KK-31 had less toxicity to PK-15 cells and had no significant effect on cell growth and reproduction.
[0131] 2. Bug experiment:
[0132] S1: Dissolve bacteriocin KK-31 in sterile water to a concentration of 100 mM as the stock solution;
[0133] S2: Weigh the body weight of G. mellonella and prepare bacteriocin KK-31 solution at final concentrations of 1280, 640, 320, 160, and 80 g / kg;
[0134] S3: bacteriocin solutions of various concentrations were injected into the body through the hind legs of the greater wax moth and placed at room temperature (25°C) for 48 h;
[0135] S4: The survival rate of G. mellonella was counted every 12 hours, and the commercial bacteriocin nisin was used as a control.
[0136] The results are as follows Fig.10 As shown, within all tested concentration ranges, G. wax moth was 100% alive. Usually, the highest concentration selected for toxicity experiments on G. wax moth for small molecule drugs is around 100g / kg. The highest concentration of bacteriocin KK-31 tested in this experiment reached 1280g / kg, and G. wax moth still survived 100%. In addition, the body surface of G. wax moth in the 1280g / kg nisin and 640g / kg nisin treatment groups turned black to a certain extent, while the body surface color of G. wax moth in the same high concentration bacteriocin KK-31 treatment group was consistent with the low concentration group, with no blackening changes.
[0137] It can be seen that bacteriocin KK-31 has a higher safety profile and is safer than the commercial bacteriocin nisin.
[0138] The above disclosure is only a preferred embodiment of the present invention, and it certainly cannot be used to limit the scope of the present invention. A person skilled in the art can understand that all or part of the processes of the above embodiment and equivalent changes made according to the claims of the present invention still fall within the scope of the invention.
[0139]
[0140]
[0141]
Claims
1. Lactobacillus sakei SNL047, deposit number is CGMCC No.27632.
2. The bacteriocin KK-31 produced by Lactobacillus sakei SNL047 according to claim 1.
3. The bacteriocin KK-31 according to claim 2, characterized in that The amino acid sequence of the bacteriocin precursor is MERISEYKVLNNNVLAGVQGGKKKKGGFFWHYFGDPIVSFGKGFIGYGKLQ V.
4. Use of Lactobacillus sakei SNL047 and bacteriocin KK-31 thereof as described in any one of claims 1 or 2 for controlling food spoilage.
5. Use of the bacteriocin KK-31 of Lactobacillus sakei SNL047 according to claim 2 in controlling pathogenic bacteria infection.
6. Use of the bacteriocin KK-31 described in claim 2 to inhibit tumor cell growth.
7. Use of the bacteriocin KK-31 described in claim 2 to inhibit virus growth.
8. Use of Lactobacillus sakei SNL047 and bacteriocin KK-31 thereof according to claim 4 in the preparation of food preservative products.
9. Use of Lactobacillus sakei SNL047 and bacteriocin KK-31 thereof according to any one of claims 5 to 7 in the preparation of pharmaceutical products.
10. The use according to claim 9, characterized in that: The pharmaceutical product is one or more of an anti-infective pharmaceutical product, an anti-tumor pharmaceutical product, and an anti-viral pharmaceutical product.
